Abstract
The first cyclic peptide discovered in animals is an antimicrobial octadecapeptide that is expressed in leukocytes of rhesus monkeys. The peptide, termed rhesus θdefensin 1 (RTD-1) is the prototype of a new family of antimicrobial peptides, which like the previously characterized α and βdefensin families, possesses broad spectrum microbicidal activities against bacteria, fungi, and protects mononuclear cells from infection by HIV-1. The cyclic θdefensin structure is essential for a number of its antimicrobial properties, as demonstrated by the markedly reduced microbicidal activities of de-cyclized θdefensin analogs. Genetic and biochemical experiments disclosed that the biosynthesis of RTD-1 results from the head-to-tail joining of two nine-amino acid peptides, each of which is donated by a separate precursor polypeptide, which are in fact C-terminally truncated pro-αdefensins. Alternate combinations of the two nonapeptides generate two additional macaque θdefensins, RTD-2 and RTD-3. Humans do not express θdefensin peptides, but mRNAs encoding at least two θdefensins are expressed in human bone marrow. However, in each case the open reading frame is interrupted by a stop codon in the signal peptide-coding region. The mature θdefensin peptide is a two-stranded βsheet that, like the α and βdefensins, is stabilized by three disulfides. However, the parallel orientation of the θ defensin disulfide arrangement allows for substantial flexibility around its short axis. Unlike α- and βdefensins, RTD-1 lacks an amphiphilic topology. This may partially explain the unusual interaction between θdefensins and phospholipid bilayers.
Keywords: theta-defensins, macrocyclic, cyclic peptides, antimicrobial
Current Protein & Peptide Science
Title: θ-Defensins: Cyclic Antimicrobial Peptides Produced by Binary Ligation of Truncated α-Defensins
Volume: 5 Issue: 5
Author(s): Michael E. Selsted
Affiliation:
Keywords: theta-defensins, macrocyclic, cyclic peptides, antimicrobial
Abstract: The first cyclic peptide discovered in animals is an antimicrobial octadecapeptide that is expressed in leukocytes of rhesus monkeys. The peptide, termed rhesus θdefensin 1 (RTD-1) is the prototype of a new family of antimicrobial peptides, which like the previously characterized α and βdefensin families, possesses broad spectrum microbicidal activities against bacteria, fungi, and protects mononuclear cells from infection by HIV-1. The cyclic θdefensin structure is essential for a number of its antimicrobial properties, as demonstrated by the markedly reduced microbicidal activities of de-cyclized θdefensin analogs. Genetic and biochemical experiments disclosed that the biosynthesis of RTD-1 results from the head-to-tail joining of two nine-amino acid peptides, each of which is donated by a separate precursor polypeptide, which are in fact C-terminally truncated pro-αdefensins. Alternate combinations of the two nonapeptides generate two additional macaque θdefensins, RTD-2 and RTD-3. Humans do not express θdefensin peptides, but mRNAs encoding at least two θdefensins are expressed in human bone marrow. However, in each case the open reading frame is interrupted by a stop codon in the signal peptide-coding region. The mature θdefensin peptide is a two-stranded βsheet that, like the α and βdefensins, is stabilized by three disulfides. However, the parallel orientation of the θ defensin disulfide arrangement allows for substantial flexibility around its short axis. Unlike α- and βdefensins, RTD-1 lacks an amphiphilic topology. This may partially explain the unusual interaction between θdefensins and phospholipid bilayers.
Export Options
About this article
Cite this article as:
Selsted E. Michael, θ-Defensins: Cyclic Antimicrobial Peptides Produced by Binary Ligation of Truncated α-Defensins, Current Protein & Peptide Science 2004; 5 (5) . https://dx.doi.org/10.2174/1389203043379459
DOI https://dx.doi.org/10.2174/1389203043379459 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Structure-Function Relationships of PEDF
Current Molecular Medicine Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Pulse Wave Velocity Assessment for Cardiovascular Risk Prognostication in ESKD: Weighting Recent Evidence
Current Vascular Pharmacology Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome
Current Pharmaceutical Design Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking!
Current Pharmaceutical Design Therapeutic Macromolecular Iron Chelators
Current Medicinal Chemistry Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
Current Medicinal Chemistry Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets Activated Lymph Nodes Recruit Blood Borne NK Cells and Effector T Cells:Implications for Adaptive T Cell Responses
Current Immunology Reviews (Discontinued) New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models
Current Drug Targets Adipokines: Therapeutic Targets for Metabolic Syndrome
Current Drug Targets Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Current Pharmaceutical Design Recent Patents on the Pichia Pastoris Expression System: Expanding the Toolbox for Recombinant Protein Production
Recent Patents on Biotechnology Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design